Development of peptidomimetic boronates as proteasome inhibitors

European Journal of Medicinal Chemistry

Volumn 64, Issue , 2013, Pages 23-34

  Micale, Nicola ^a   Ettari, Roberta ^b   Lavecchia, Antonio ^c   Di Giovanni, Carmen ^c   Scarbaci, Kety ^a   Troiano, Valeria ^a   Grasso, Silvana ^a   Novellino, Ettore ^c   Schirmeister, Tanja ^d   Zappalà, Maria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Docking studies; Peptidomimetic boronates; Proteasome inhibitors

Indexed keywords

(1 METHYL 1,2,3,4 TETRAHYDRO 5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)ACETIC ACID; (2 OXO 2H PYRIDIN 1 YL)ACETIC ACID; (4 DIETHYLAMINO 2 OXO 2H PYRIDIN 1 YL)ACETIC ACID ETHYLESTER; (4 PHENYLAMINO 2 OXO 2H PYRIDIN 1 YL) ACETIC ACID ETHYLESTER; (5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)ACETIC ACID; (8 BROMO 5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)ACETIC ACID; 1 [(8 BROMO 5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)ACETAMIDO] 3 METHYLBUTYLBORONIC ACID; 1 [2 (2 OXO 2H PYRIDIN 1 YL)ACETAMIDO] 3 METHYLBUTYLBORONIC ACID; 1 [2 (2 OXO 2H PYRIDIN 1 YL)ACETAMIDO] 3 METHYLBUTYLBORONIC ACID PINANEDIOL ESTER; 1 [2 (4 DIETHYLAMINO 2 OXO 2H PYRIDIN 1 YL)ACETAMIDO] 3 METHYLBUTYLBORONIC ACID; 1 [2 (5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL); 1 [2 (5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)PROPANAMIDO] 3 METHYLBUTYLBORONIC ACID; 1 [2 [4 (4 ALLYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETAMIDO] 3 METHYLBUTYLBORONIC ACID PINANEDIOL ESTER; 1 [2 [4 (4 METHYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETAMIDO] 3 METHYLBUTYLBORONIC ACID PINANEDIOL ESTER; 1 [2 [4 (MORPHOLIN 4 YL) 2 OXO 2H PYRIDIN 1 YL]ACETAMIDO]3 METHYLBUTYLBORONIC ACID; 1 [2 [4 (PIPERIDIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETAMIDO]3 METHYLBUTYLBORONIC ACID; 2 (5 OXO 5H 1,6 NAPHTHYRIDIN 6 YL)PROPIONIC ACID; 4 (4 ALLYLPIPERAZIN 1 YL) 1H PYRIDIN 2 ONE; 4 DIETHYLAMINO 1H PYRIDIN 2 ONE; 4 PHENYLAMINO 1H PYRIDIN 2 ONE; [4 (4 ALLYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID; [4 (4 ALLYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID ETHYLESTER; [4 (4 METHYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID; [4 (4 METHYLPIPERAZIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID ETHYL ESTER; [4 (MORPHOLIN 4 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID ETHYLESTER; [4 (PIPERIDIN 1 YL) 2 OXO 2H PYRIDIN 1 YL]ACETIC ACID; BORTEZOMIB; CHYMOTRYPSIN A; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME INHIBITION; MOLECULAR DOCKING; PROTEIN DEGRADATION; SYNTHESIS;

BORON COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDOMIMETICS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877052432     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.032     Document Type: Article

References (30)

1. L. Borissenko, and M. Groll 20S Proteasome and its inhibitors: crystallographic knowledge for drug development Chem. Rev. 107 2007 687 717
2. A.M. Weissman, N. Shabek, and A. Ciechanover The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation Nat. Rev. Mol. Cell Biol. 12 2011 605 620
3. A. Ciechanover Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting Neurodegener. Dis. 10 2012 7 22
4. A. Field-Smith, G.J. Morgan, and F.E. Davies Bortezomib (Velcade™) in the treatment of multiple myeloma Ther. Clin. Risk Manag. 2 2006 271 279
5. R.C. Kane, R. Dagher, A. Farrell, C.W. Ko, R. Sridhara, R. Justice, and R. Pazdur Bortezomib for the treatment of mantle cell lymphoma Clin. Cancer Res. 13 2007 5291 5294
6. G.L. Olson, D.R. Bolin, M.P. Bonner, M. Bös, C.M. Cook, D.C. Fry, B.J. Graves, M. Hatada, D.E. Hill, M. Kahn, V.S. Madison, V.K. Rusiecki, R. Sarabu, J. Sepinwall, G.P. Vincent, and M.E. Voss Concepts and progress in the development of peptide mimetics J. Med. Chem. 36 1993 3039 3049
7. M. Groll, C.R. Berkers, H.L. Ploegh, and H. Ovaa Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 14 2006 451 456
8. Y.H. Kim, Y. Kim, S. Chang, B. Kim, and J. Heo A general strategy for the synthesis of amino-substituted 2-pyridones using a palladium-catalyzed amination reaction Bull. Korean Chem. Soc. 28 2007 777 782
9. D.S. Matteson, P.K. Jesthi, and K.M. Sadhu Synthesis and properties of pinanediol α-amido boronic esters Organometallics 3 1984 1284 1288
10. H.D.H. Showalter Ready access to 7,8-dihydro- and 1,2,3,4-tetrahydro-1,6- naphthyridine-5(6H)-ones from simple pyridine precursors J. Heterocycl. Chem. 43 2006 1311 1317
11. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 59 1999 2615 2622
12. A.F. Kisselev, A. Callard, and A.L. Goldberg Importance of different active sites in protein breakdown by 26S proteasomes and the efficacy of proteasome inhibitors varies with the protein substrate J. Biol. Chem. 281 2006 8582 8590
13. M. Britton, M.M. Lucas, S.L. Downey, M. Screen, A.A. Pletnev, M. Verdoes, R.A. Tokhunts, O. Amir, A.L. Goddard, P.M. Pelphrey, D.L. Wright, H.S. OverKleeft, and A.F. Kisselev Selective inhibitor of proteasome's caspase-like sites sensitises cells to specific inhibition of chymotripsin-like sites Chem. Biol. 16 2009 1278 1289
14. F. Parlati, S.J. Lee, M. Aujay, E. Suzuk, K. Levitsky, J.B. Lorens, D.R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, K.D. Shenk, and M.K. Bennett Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114 2009 3439 3447
15. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
16. GOLD, Version 5.1 2012 The Cambridge Crystallographic Data Centre Cambridge, U.K.
17. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins: Struct. Funct. Genet. 52 2003 609 623
18. G. Fracchiolla, A. Laghezza, L. Piemontese, P. Tortorella, F. Mazza, R. Montanari, G. Pochetti, A. Lavecchia, E. Novellino, S. Pierno, D. Conte Camerino, and F. Loiodice New 2-aryloxy-3-phenyl-propanoic acids as PPAR α/γ dual agonists with improved potency and reduced adverse effects on skeletal muscle function J. Med. Chem. 52 2009 6382 6393
19. C. La Motta, S. Sartini, L. Mugnaini, S. Salerno, F. Simorini, S. Taliani, A.M. Marini, F. Da Settimo, A. Lavecchia, E. Novellino, L. Antonioli, M. Fornai, C. Blandizzi, and M. Del Tacca Exploiting the pyrazolo[3,4-d] pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors J. Med. Chem. 52 2009 1681 1692
20. L. Porcelli, F. Gilardi, A. Laghezza, L. Piemontese, N. Mitro, A. Azzariti, F. Altieri, L. Cervoni, G. Fracchiolla, M. Giudici, U. Guerrini, A. Lavecchia, R. Montanari, C. Di Giovanni, A. Paradiso, G. Pochetti, G.M. Simone, P. Tortorella, M. Crestani, and F. Loiodice Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity J. Med. Chem. 55 2012 37 54
21. M.G. Perrone, P. Vitale, P. Malerba, A. Altomare, A. Lavecchia, C. Di Giovanni, E. Novellino, and A. Scilimati Core ring nature in diarylheterocycle COX-1 inhibitors Chem. Med. Chem. 7 2012 629 641
22. Y.Q. Zhu, X. Zhao, X.R. Zhu, G. Wu, Y.J. Li, Y.H. Ma, Y.X. Yuan, J. Yang, Y. Hu, L. Ai, and Q.Z. Gao Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of α-amino acid boronates J. Med. Chem. 52 2009 4192 4199
23. R.M. Rydzewski, L. Burrill, R. Mendonca, J.T. Palmer, M. Rice, R. Tahilramani, K.E. Bass, L. Leung, E. Gjerstad, J.W. Janc, and L. Pan Optimization of subsite binding to the 5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1, 3, 4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors J. Med. Chem. 49 2006 2953 2968
24. K.E. Riley, and P.J. Hobza Strength and character of halogen bonds in protein-ligand complexes Cryst. Growth Des. 11 2011 4272 4278
25. C. Bissantz, B. Kuhn, and M.A. Stahl J. Med. Chem. 53 2010 5061 5084
26. A. Terajima, T. Kajashiki, and T. Kato Preparation of 2-hydroxypyridines and 2-(1H)-pyridones by hydrogenation of aralkyloxypyridines Jpn. Kokai Tokkyo Koho 4 March 1997 JP 09059254 A2
27. R.J. Payne, E.M.M. Bulloch, A.D. Abell, and C. Abell Design and synthesis of aromatic inhibitors of anthranilate synthase Org. Biomol. Chem. 3 2005 3629 3635
28. Maestro, Version 9.2 2011 Schrödinger, LLC New York, NY
29. C.C. Huang, G.S. Couch, E.F. Pettersen, and T.E. Ferrin Chimera: an extensible molecular modelling application constructed using standard components Pacif. Symp. Biocomput. 1 1996 724 http://www.cgl.ucsf.edu/chimera
30. W.L. DeLano, The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA, USA, http://www.pymol.org/. della Ricerca Scientifica e Tecnologica